Melanotan-2 (MT-II)
Melanotan-2 (MT-II) is a cyclic lactam α-MSH analog and nonselective melanocortin receptor agonist studied in pigmentation, feeding, and sexual-function models; the research catalog lists it at https://onesourcepeptides.com/product/melanotan-2.
MT-II entered the melanocortin literature as a designed cyclic probe. Al-Obeidi et al., Journal of Medicinal Chemistry, 1989 (PMID 2555512) report a series of lactam-bridged α-MSH fragment analogs built around the His-D-Phe-Arg-Trp pharmacophore; the Asp5–Lys10 23-membered ring compound that became Melanotan-II showed roughly 100-fold higher melanotropic potency than α-MSH in the lizard-skin bioassay and prolonged residual activity relative to the linear hormone.
Early human pharmacology and central melanocortin work followed. Dorr et al., Life Sciences, 1996 (PMID 8637402) evaluated subcutaneous MT-II in a pilot phase-I study in healthy men and reported measurable increases in skin pigmentation after a short alternating-day course, alongside receptor-consistent observations such as stretching/yawning and intermittent erectile activity. In animal feeding models, Fan et al., Nature, 1997 (PMID 8990120) used MT-II as a melanocortin agonist to inhibit food intake and block the agouti obesity phenotype, establishing the peptide as a standard central MC3R/MC4R probe.
Sexual-function pharmacology extended the same scaffold. Wessells et al., Journal of Urology, 1998 (PMID 9679884) tested Melanotan-II in a double-blind crossover study in men with psychogenic erectile dysfunction and reported clinically apparent erections versus placebo under RigiScan monitoring. Related notes cover PT-141 (a related melanocortin agonist developed from the MT-II lineage) and Kisspeptin-10, and lot identity belongs on the certificate of analysis for the vial in hand (see Are research peptides third-party tested?). Melanotan-2 on the catalog is laboratory research supply only. This note summarizes published melanocortin-receptor research and is not dosing, reconstitution, or human-use guidance.